Michael Thomas Heffernan
CIK 1448914 · Chairman, President and CEO · last filed 2026-06-04
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$8.06M
Companies
13
Total Filings
116
Lifetime Open-Market Net
-$25.71M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| AVTX | Director | — | $14.76 | — | $0 | 3 | 2026-06-04 |
| TRVI | Director | 3,851 | $14.21 | $54.7K | $25.0K | 10 | 2026-06-04 |
| ENGNW | Director | — | $0.27 | — | $0 | 1 | 2025-07-10 |
| BHVN | Director | 15,178 | $11.28 | $171.2K | $0 | 10 | 2025-05-07 |
| COLL | Director | 213,371 | $34.64 | $7.39M | -$15.14M | 17 | 2025-02-12 |
| SYBX | Director | — | $0.69 | — | $0 | 4 | 2023-06-26 |
| Biohaven Pharmaceutical Holding Co Ltd. (BHVNw) Delisted | Director | — | — | — | $0 | 1 | 2022-10-03 |
| AKBA | Director | 48,586 | $0.92 | $44.9K | $0 | 4 | 2021-06-03 |
| ESPR | Director | 126,623 | $3.15 | $398.9K | -$10.59M | 31 | 2019-08-13 |
| KERYX BIOPHARMACEUTICALS INC (KERX) Delisted | Director | 0 | — | — | $0 | 4 | 2018-12-13 |
| Ocata Therapeutics, Inc. (OCAT) Delisted | Director | 0 | — | — | $0 | 7 | 2016-02-11 |
| CORNERSTONE THERAPEUTICS INC (CRTX) Delisted | Director | — | $1.95 | — | $0 | 7 | 2014-02-04 |
| CORNERSTONE THERAPEUTICS INC (CRTXD) Delisted | Director | — | — | — | $0 | 1 | 2008-11-04 |
Recent Filings · Page 8 of 12
116 filingsForm 4 transactions across all companies, newest first.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2018-03-01 | ESPR | Tax (F) | −4,050 | -$88.2K | EDGAR |
| 2018-02-06 | ESPR | Tax (F) | −788 | -$18.4K | EDGAR |
| 2018-01-29 | ESPR | Grant (A) | +76,044 | $10.6K | EDGAR |
| 2018-01-23 | ESPR | Sell (S) | −20,000 | -$500.2K | EDGAR |
| 2018-01-19 | ESPR | Sell (S) | −20,000 | -$450.0K | EDGAR |
| 2017-11-17 | ESPR | Sell (S) | −50,000 | -$776.5K | EDGAR |
| 2017-08-04 | ESPR | Mixed | −96 | -$2.3K | EDGAR |
| 2017-06-20 | KERYX BIOPHARMACEUTICALS INC (KERX) Delisted | Grant (A) | +10,000 | $0 | EDGAR |
| 2017-03-21 | ESPR | Tax (F) | −1,472 | -$22.0K | EDGAR |
| 2017-02-14 | ESPR | Grant (A) | +55,000 | $0 | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.